<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01327378</url>
  </required_header>
  <id_info>
    <org_study_id>H-C-2009-007</org_study_id>
    <nct_id>NCT01327378</nct_id>
  </id_info>
  <brief_title>The Incretin Effect in Patients With Kidney Impairment</brief_title>
  <acronym>UREMINC</acronym>
  <official_title>The Incretin Effect in Non-diabetic Patients With Severe Renal Impairment Depending on Chronic Dialysis Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study explores the incretin effect; a central mechanism of sugar metabolism.
      People with type 2 diabetes have a markedly reduced incretin effect, while the incretin
      effect never has been studied in patients with severe chronic renal failure. Non-diabetic
      patients with severe kidney failure and patients with diabetes and normal kidney function
      share several pathophysiological traits, including decreased sensitivity to insulin, fasting
      hyperinsulinaemia and impaired beta cell function. The investigators expect the incretin
      effect to be affected in patients with chronic renal failure without diabetes, which in time
      can result in therapeutic changes in this group of patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The novel and original aspect of this investigator initiated study is the focus on incretin
      (patho)physiology in an uraemic milieu. In this first of 5 substudies (separate notification
      and registration) the investigators explore the incretin effect. Our hypothesis is that it is
      impaired in non-diabetic patients in chronic dialysis treatment.

      The prevalence of type 2 diabetes mellitus (T2DM) is rapidly increasing worldwide. In
      addition to reduced insulin sensitivity and beta cell dysfunction, T2DM is characterized by a
      severely impaired incretin effect. The incretin effect refers to the insulinotropic action of
      the nutrient-released incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent
      insulinotropic peptide (GIP). Both hormones are secreted from intestinal endocrine mucosal
      cells. The incretin effect is defined as the difference in insulin secretory responses
      between oral and isoglycaemic intravenous (iv) glucose challenges. In healthy individuals it
      accounts for as much as 70% of insulin secreted in response to oral glucose, whereas patients
      with T2DM exhibit an incretin effect in the range of 0 to 30%. The incretin hormone GLP-1 has
      a potent blood glucose-lowering effect in patients with T2DM. However, following secretion of
      GLP-1, the ubiquitous enzyme dipeptidyl peptidase-4 (DPP-4) rapidly cleaves the hormone, by
      which it is completely inactivated. This has formed the basis for new pharmacological agents
      blocking DPP-4 (DPP-4 inhibitors) or DPP-4 resistant GLP-1 receptor agonists. Long-term
      treatment has showed positive effect on glycaemic control and risk factors of cardiovascular
      diseases in patients with T2DM.

      These effects may be applicable also in patients with end-stage renal disease (ESRD) because
      patients with T2DM and normal kidney function and non-diabetic patients with ESRD show
      several identical characteristics. These include decreased insulin sensitivity,
      hyperinsulinaemia and impaired beta cell function. The incretin effect has only to a small
      extent been investigated in patients with ESRD.

      The single most frequent cause of ESRD and need of chronic maintenance dialysis is diabetic
      nephropathy. In the U.S. more than 50% of patients in dialysis have diabetes compared with
      about 23% in Denmark. The life expectancy of dialysis patients with T2DM is severely reduced
      with a median survival of 2 to 4 years and there is no treatment documented to significantly
      improve this poor prognosis. The most common cause of death in this group of patients is
      related to cardiovascular disease that seems to result from death of causes different from
      classical atherosclerosis. So far intervention directed towards hypertension, dyslipidaemia
      and other classical risk factors have showed divergent and primarily negative results.

      There is therefore an unmet medical need to find new treatments to protect these patients
      from cardiovascular disease and premature death.

      Improving the glycaemic control using incretin-based therapies has the potential to meet this
      medical need. The incretin hormones and their metabolites are however to a large extent
      excreted by the kidneys and this may lead to problems (or benefits!) when administered to
      patients without kidney function or with severely reduced kidney function. The present
      knowledge about the incretin effect and incretin hormone physiology as well as
      pharmacokinetics, clinical effects and side effects of GLP-1 analogues in patients with
      reduced kidney function is limited and the few studies available are predominantly confined
      to patients with only mild or moderately reduced kidney function. The investigators will
      explorer basic and pharmacologic aspects in patients with severe reduced kidney function
      depending on chronic maintenance dialysis treatment. Before any potential treatment can be
      initiated, the investigators need basic information on how the incretin system is affected by
      an uraemic milieu. Current and succeeding substudies will provide us with that information.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incretin effect</measure>
    <time_frame>Minimum 3 days and maximum 3 weeks between the two examination days. Cross-sectional design. No follow up.</time_frame>
    <description>IE= 100%*(iAUC,OGTT - iAUC,IIGI)/iAUC,OGTT Assessed at two separate examination days. Day 1: Oral glucose tolerance test (OGTT), Day 2: Intravenous isoglycaemic glucose infusion (IIGI).
Data will be presented when all analyses have been performed. Estimated in May 2011.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastric-induced glucose disposal (GIGD)</measure>
    <time_frame>Minimum 3 days and maximum 3 weeks between the two examination days. Cross-sectional design. No follow up.</time_frame>
    <description>GIGD=100%*(glucose,OGTT-glucose,IIGI)/glucose,OGTT) Assessed at two separate examination days. Day 1: Oral glucose tolerance test (OGTT), Day 2: Intravenous isoglycaemic glucose infusion (IIGI).
Data will be presented when all analyses have been performed. Estimated in May 2011.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>Dialysis, normal glucose tolerance</arm_group_label>
    <description>Chronic dialysis treatment, N=10 OGTT,120 min &lt; 7.8 mmol/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dialysis, impaired glucose tolerance</arm_group_label>
    <description>Chronic dialysis treatment, N=10 OGTT,120 min 7.7&lt;11.1 mmol/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control, normal glucose tolerance</arm_group_label>
    <description>Healthy Control subjects, N=10 OGTT,120 min &lt;7.8 mmol/L</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma (10 ml per participant)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        3 groups

          1. Chronic hemodialysis treatment. Normal glucose tolerance (NGT). N=10

          2. Chronic hemodialysis treatment. Impaired glucose tolerance (IGT). N=10

          3. Healthy control subjects. Normal glucose tolerance. N=10

        Glucose tolerance is evaluated at the screeningday. A 75 gram oral glucose tolerance test
        (OGTT) is performed and the 120 minute value sets the glucose tolerance. NGT: &lt; 7.8 mmol/L,
        IGT: &gt; 7.7 mmol/L and &lt; 11.1 mmol/L (according to WHO guidelines).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female; age: 18 - 90 years

          -  CKD stage 5 (CrCL &lt; 15 ml/min) in chronic haemodialysis (minimum 3 months)

          -  NGT or IGT (diagnosed according to WHO criteria)

          -  Body mass index 18.5 - 28 kg/m2

        Exclusion Criteria:

          -  Type 1 or 2 diabetes mellitus

          -  Pancreatitis

          -  Medication with influence on insulin secretion and/or glucose metabolism

          -  Previous or actual malignancy

          -  Inflammatory bowel disease

          -  Congestive heart failure (NYHA III-IV)

          -  Previous bowel resection

          -  Severe hypertension

          -  Impaired liver function

          -  Haemoglobin &lt; 6.5 mmol/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Feldt-Rasmussen, Prof, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Department of Nephrology, Rigshospitalet, University of Copenhagen, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nephrology P 2131, Rigshospitalet</name>
      <address>
        <city>Copenhagen Ã˜</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2011</study_first_submitted>
  <study_first_submitted_qc>March 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2011</study_first_posted>
  <last_update_submitted>March 31, 2011</last_update_submitted>
  <last_update_submitted_qc>March 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Thomas Idorn/M.D. PhD student</name_title>
    <organization>Department of Nephrology, Rigshospitalet, University of Copenhagen, Denmark</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

